Definitive Healthcare (DH)

• Market cap: $366M
• 1 day: -4.85%
• 5 days: -7.92%
• 1 month: 25.10%
• 3 months: -36.18%
• 6 months: -26.12%
• Year to date: -23.79%
• 1 year: -44.42%
• 5 years: -92.75%
• 10 years: -92.75%
• Sector: Healthcare
• Industry: Health Information Services

About: Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

Employees: 782

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

90% more call options, than puts

Call options by funds: $38K | Put options by funds: $20K

50% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 20

7% more funds holding

Funds holding: 127 [Q4 2024] → 136 (+9) [Q1 2025]

0.34% less ownership

Funds ownership: 90.88% [Q4 2024] → 90.54% (-0.34%) [Q1 2025]

2% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 44

32% less capital invested

Capital invested by funds: $431M [Q4 2024] → $295M (-$136M) [Q1 2025]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 4% downside
• Avg. target: $3.20 2% upside
• High target: $3.40 8% upside

2 analyst ratings

• positive: 0 0%
• neutral: 1 50%
• negative: 1 50%

Goldman Sachs Kash Rangan	8% upside $3.40	Neutral Maintained	12 May 2025
Barclays Saket Kalia	4% downside $3	Underweight Maintained	3 Mar 2025